A total of 73 patients diagnosed with LM were treated with osimertinib, including 64 patients evaluable for the LM efficacy set—T790M negative (n = 62) and T790M positive (n = 2). The median OS in the ...

In total, 5,708 patients from five randomized phase III trials were included. Two MMAI algorithms were evaluated: (1) the distant metastasis (DM) MMAI model optimized to predict risk of DM, and (2) ...

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or ...

Taletrectinib: TRUST in the Continued Evolution of Treatments for ROS1 Fusion–Positive Lung Cancer In the article that accompanies this editorial, O'Brien et al 18 use a variety of methods to address ...

Addressing Barriers in Palliative Care for Rural and Underserved Communities Changes to sexual function after cancer treatment are extremely prevalent, affecting up to 90% of female patients with ...

Dose escalation of KY-0118, PD-1, and IL-2v due-target fusion protein in patients with advanced renal clear cell carcinoma, urothelial carcinoma, and malignant melanoma. This is an ASCO Meeting ...

A safety cohort received Gem 1,000 mg/m 2 and Nab 125 mg/m 2 on days 1, 8, and 15, and Toc 8 mg/kg on day 1 for each 28-day cycle. Participants with modified Glasgow prognostic scores of 1 or 2 were ...

Characterization of HER2 alterations in lung adenocarcinoma.

Abbreviations: ALP, alkaline phosphatase; ANC, absolute neutrophil count; CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; HGB, hemoglobin ...

Despite being a cornerstone of cancer treatment advancement, clinical trials remain inaccessible for many patients because of structural, socioeconomic, and systemic barriers. In this ...

Nephrotoxicity Surveillance for Childhood and Young Adult Survivors of Cancer: Recommendations From the International Late Effects of Childhood Cancer Guideline Harmonization Group We derived disease ...

Creating a Proxy for Baseline Eastern Cooperative Oncology Group Performance Status in Electronic Health Records for Comparative Effectiveness Research in Advanced Non–Small Cell Lung Cancer ...